Society on Sarcopenia, Cachexia and Wasting Disorders

Last updated

Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) is an international and multidisciplinary non-profit organization, created in 2008 that focuses on cachexia [1] and sarcopenia. [2] As they are often under-diagnosed, patient groups aim to improve their awareness. [3] Cachexia has been coined the "last illness" [4] and is sometimes called "body wasting". [5] The prevalence of cachexia ranges from 5–15% in end-stage chronic heart failure to 50–80% in advanced malignant cancer. [6] It is estimated that 5 Million Americans have the condition and cachexia frequently occurs in patients with chronic kidney disease, chronic obstructive pulmonary disease (COPD), HIV, Multiple sclerosis, neurological diseases, and rheumatoid arthritis. [7] Mortality rates of cachexia patients range from 15 to 25% per year in severe COPD, 20–40% per year in patients with chronic heart failure or chronic kidney disease, to 20–80% per year in cancer cachexia. [8] The SCWD was founded in 2008 on the initiative of Prof. Stefan D. Anker [9] in Germany and Dr. John E. Morley [10] in the US. It is made up of an international and multidisciplinary group of healthcare professionals in the fields of sarcopenia, cachexia and muscle wasting. [11] As of 2018, the society had 150 members.

Contents

The purpose and objectives of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) are to:

The SCWD is a non-profit scientific organization (501 c3) [14] registered in the United States of America and Switzerland. The president is Prof. Stefan Anker, Germany who is also vice-president of the European Society of Cardiology, [15] the vice-president is Dr. John Morley, USA and the treasurer is Prof. Andrew J. Coats, United Kingdom who particularly investigated cardiac cachexia at an early stage. [16]
The Board consists of:
Stefan D. Anker (President [17] ) – Berlin, Germany
Josep M. Argiles – Barcelona, Spain
Vickie E. Baracos – Edmonton, Canada
Andrew J. S. Coats (Treasurer) – Norwich, UK
Wolfram Doehner – Berlin, Germany
William J. Evans [18] – Duke University, US
Luigi Ferrucci [19] – Baltimore, US
David J. Glass – Boston, US
Akio Inui – Kobe, Japan
Aminah Jatoi – Rochester, US
Kamyar Kalantar-Zadeh – Los Angeles, US
John E. Morley (vice-president) – St. Louis, US
Filippo Rossi-Fanelli – Rome, Italy
Florian Strasser – St. Gallen, Switzerland
Stephan von Haehling – Göttingen, Germany

Prof Ken Fearon was a board member until he died in September 2016. [20] He received the Hippocrates Award from the Society. [21] Professor Fearon was particularly involved in cancer cachexia: leading an international consensus. [22]

Educational initiatives

Conferences

Since 2000 the SCWD has organized several international conferences. [23] [24] In December 2009, the 5th Cachexia conference [25] took place in Barcelona, Spain. In 2011, the 7th conference took place in Italy. [26] One of them took place in Kobe, Japan. [27] These conferences took place every two years until 2015, when in Paris [28] it was decided to organize the conferences annually instead. [29] The location of the 2016 congress is Berlin on 10–11 December 2016. [30] The programme includes a statistical seminar, a mentor or career session and sessions on cachexia, sarcopenia and muscle wasting. [31]

It addresses frailty, sarcopenia and cachexia resulting from the following diseases or chronic conditions: Cancer, Cardiovascular Disease, Death, Dying & Grief, Dementia/Alzheimer's Disease, Diabetes, Heart Failure and Ageing. [32] Update on Anabolic and Related Therapies are also provided. [33] Results of clinical trials are also presented, such as data from a Phase II clinical trial of MT-102 in cancer-related cachexia presented in Kobe in 2013. [34] The latest conference took place in Maastricht in 2018. In 2019, the international conference will take place in Berlin.

Target audience: Internists, Oncologists, Geriatricians, Cardiologists, Nephrologists, Palliative care specialists, Nurse Practitioners and Primary Care Providers.

A charity dinner is sometimes organised during SCWD conferences such as in 2011 in Milan with the participation of Lisa Niemi. [35]

Posters: each meeting features 120-200 posters. [36]

The SCWD releases regular highlights of its meetings. [37]

Consensus meetings

Since 2006, the SCWD has also organized several consensus meetings to address issues related to the definition of cachexia, sarcopenia [38] as well the regulatory pathways for treatment development in cachexia, sarcopenia and the syndrome of muscle wasting. [39]
The major objective was to bring together a multi-disciplinary team of experts in order to develop, as a united body, a consensus of statements [40] based on the following topics:

This consensus gathered together about 30 international scientists, including representatives from regulatory authorities. The invited experts are well-recognized academic leaders in geriatrics, oncology, cardiology, pulmonology and regulatory issues.
These consensus projects aimed to facilitate the future design and performance of clinical trials in the fields of cachexia and sarcopenia [44] They also generated recommendations for nutritional management. [45]

Journal

The Journal of Cachexia, Sarcopenia and Muscle (JCSM) published by Wiley-Blackwell is the official journal of SCWD. [46] It was created in 2010. [47] According to the Journal Citation Reports , the journal has a 2017 impact factor of 12.511. JCSM has seen an increase in citations and submissions in 2016. [48] It is ranked in the first 10 journals for all journals in the field of "medicine, general and internal. [49] Two daughter journals also exist: JCSM—Clinical Reports Archived 3 February 2019 at the Wayback Machine started in July 2016 and JCSM—Rapid Communications.

About muscle wasting, cachexia and sarcopenia

Cachexia is a major issue, especially in the elderly. [50] Cachexia can occur in most major diseases including infections, cancer, heart disease, chronic kidney disease, chronic obstructive pulmonary disease, and stroke. [51] Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to poor quality of life and increased morbidity/mortality. Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia. [52] Sarcopenia and cachexia represent the major causes of muscle-wasting disorders. It has been known for millennia that muscle and fat wasting leads to poor outcomes, including deaths in chronic disease states.
It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance, which are also common features of the frailty syndrome. [53]
Cachexia and sarcopenia are both characterized by an important muscle dysfunction and weakness [54] that lead to increased morbidity and mortality. [55] The cost of muscle wasting is high. [56]

Related Research Articles

<span class="mw-page-title-main">ACE inhibitor</span> Class of medications used primarily to treat high blood pressure

Angiotensin-converting-enzyme inhibitors are a class of medication used primarily for the treatment of high blood pressure and heart failure. This class of medicine works by causing relaxation of blood vessels as well as a decrease in blood volume, which leads to lower blood pressure and decreased oxygen demand from the heart.

<span class="mw-page-title-main">Exercise</span> Physical activity that improves health

Exercise is physical activity that enhances or maintains fitness and overall health. It is performed for various reasons, including weight loss or maintenance, to aid growth and improve strength, develop muscles and the cardiovascular system, hone athletic skills, improve health, or simply for enjoyment. Many individuals choose to exercise outdoors where they can congregate in groups, socialize, and improve well-being as well as mental health.

<span class="mw-page-title-main">Cachexia</span> Syndrome causing muscle loss not entirely reversible

Cachexia is a complex syndrome associated with an underlying illness, causing ongoing muscle loss that is not entirely reversed with nutritional supplementation. A range of diseases can cause cachexia, most commonly cancer, congestive heart failure, chronic obstructive pulmonary disease, chronic kidney disease, and AIDS. Systemic inflammation from these conditions can cause detrimental changes to metabolism and body composition. In contrast to weight loss from inadequate caloric intake, cachexia causes mostly muscle loss instead of fat loss. Diagnosis of cachexia can be difficult due to the lack of well-established diagnostic criteria. Cachexia can improve with treatment of the underlying illness but other treatment approaches have limited benefit. Cachexia is associated with increased mortality and poor quality of life.

<span class="mw-page-title-main">Weight loss</span> Reduction of the total body mass

Weight loss, in the context of medicine, health, or physical fitness, refers to a reduction of the total body mass, by a mean loss of fluid, body fat, or lean mass. Weight loss can either occur unintentionally because of malnourishment or an underlying disease, or from a conscious effort to improve an actual or perceived overweight or obese state. "Unexplained" weight loss that is not caused by reduction in calorific intake or increase in exercise is called cachexia and may be a symptom of a serious medical condition.

<span class="mw-page-title-main">Metabolic acidosis</span> Medical condition

Metabolic acidosis is a serious electrolyte disorder characterized by an imbalance in the body's acid-base balance. Metabolic acidosis has three main root causes: increased acid production, loss of bicarbonate, and a reduced ability of the kidneys to excrete excess acids. Metabolic acidosis can lead to acidemia, which is defined as arterial blood pH that is lower than 7.35. Acidemia and acidosis are not mutually exclusive – pH and hydrogen ion concentrations also depend on the coexistence of other acid-base disorders; therefore, pH levels in people with metabolic acidosis can range from low to high.

β-Hydroxy β-methylbutyric acid Chemical compound

β-Hydroxy β-methylbutyric acid (HMB), otherwise known as its conjugate base, β-hydroxyβ-methylbutyrate, is a naturally produced substance in humans that is used as a dietary supplement and as an ingredient in certain medical foods that are intended to promote wound healing and provide nutritional support for people with muscle wasting due to cancer or HIV/AIDS. In healthy adults, supplementation with HMB has been shown to increase exercise-induced gains in muscle size, muscle strength, and lean body mass, reduce skeletal muscle damage from exercise, improve aerobic exercise performance, and expedite recovery from exercise. Medical reviews and meta-analyses indicate that HMB supplementation also helps to preserve or increase lean body mass and muscle strength in individuals experiencing age-related muscle loss. HMB produces these effects in part by stimulating the production of proteins and inhibiting the breakdown of proteins in muscle tissue. No adverse effects from long-term use as a dietary supplement in adults have been found.

<span class="mw-page-title-main">Sarcopenia</span> Muscle loss due to ageing or immobility

Sarcopenia is a type of muscle loss that occurs with aging and/or immobility. It is characterized by the degenerative loss of skeletal muscle mass, quality, and strength. The rate of muscle loss is dependent on exercise level, co-morbidities, nutrition and other factors. The muscle loss is related to changes in muscle synthesis signalling pathways. It is distinct from cachexia, in which muscle is degraded through cytokine-mediated degradation, although the two conditions may co-exist. Sarcopenia is considered a component of frailty syndrome. Sarcopenia can lead to reduced quality of life, falls, fracture, and disability.

<span class="mw-page-title-main">Protein supplement</span>

A protein supplement is a dietary supplement or a bodybuilding supplement, and usually comes in the form of a protein bar, protein powder, and even readily available as a protein shake. Usually made from whey, plant, and/or meat sources.

<span class="mw-page-title-main">Muscle atrophy</span> Medical condition

Muscle atrophy is the loss of skeletal muscle mass. It can be caused by immobility, aging, malnutrition, medications, or a wide range of injuries or diseases that impact the musculoskeletal or nervous system. Muscle atrophy leads to muscle weakness and causes disability.

<span class="mw-page-title-main">Protein–energy malnutrition</span> Medical condition

Protein–energy undernutrition (PEU), once called protein-energy malnutrition (PEM), is a form of malnutrition that is defined as a range of conditions arising from coincident lack of dietary protein and/or energy (calories) in varying proportions. The condition has mild, moderate, and severe degrees.

<span class="mw-page-title-main">Frailty syndrome</span> Weakness in elderly person

Frailty is a common geriatric syndrome that embodies an elevated risk of catastrophic declines in health and function among older adults. Frailty is a condition associated with ageing, and it has been recognized for centuries. It is a marker of a more widespread syndrome of frailty, with associated weakness, slowing, decreased energy, lower activity, and, when severe, unintended weight loss. As a frequent clinical syndrome in the elderly, various health risks are linked to health deterioration and frailty in older age, such as falls, disability, hospitalization, and mortality. Generally, frailty refers to older adults who lose independence. It also links to the experiences of losing dignity due to social and emotional isolation risk. Frailty has been identified as a risk factor for the development of dementia.

<span class="mw-page-title-main">Selective androgen receptor modulator</span> Class of pharmaceutical drugs

Selective androgen receptor modulators (SARMs) are a class of drugs that selectively activate the androgen receptor in specific tissues, promoting muscle and bone growth while having less effect on male reproductive tissues like the prostate gland.

Sarcopenic obesity is a medical condition which is defined as the presence of both sarcopenia and obesity. Sarcopenia refers to the presence of low muscle mass and either low muscular strength or low physical performance. When this is accompanied by a high fat mass the condition is known as sarcopenic obesity.

<span class="mw-page-title-main">Enobosarm</span> Investigational selective androgen receptor modulator

Enobosarm, also formerly known as ostarine and by the developmental code names GTx-024, MK-2866, and S-22, is a selective androgen receptor modulator (SARM) which is under development for the treatment of androgen receptor-positive breast cancer in women and for improvement of body composition in people taking GLP-1 receptor agonists like semaglutide. It was also under development for a variety of other indications, including treatment of cachexia, Duchenne muscular dystrophy, muscle atrophy or sarcopenia, and stress urinary incontinence, but development for all other uses has been discontinued. Enobosarm was evaluated for the treatment of muscle wasting related to cancer in late-stage clinical trials, and the drug improved lean body mass in these trials, but it was not effective in improving muscle strength. As a result, enobosarm was not approved and development for this use was terminated. Enobosarm is taken by mouth.

Coaches are professional tutors who have expertise in their preferred area of study. Weight loss coaches, specifically, have clientele within the health and fitness industry.

Kamyar Kalantar-Zadeh is a US American physician doing research in nephrology, kidney dialysis, nutrition, and epidemiology. He is best known as a specialist in kidney disease nutrition and chronic kidney disease and for his hypothesis about the longevity of individuals with chronic disease states, also known as reverse epidemiology including obesity paradox. According to this hypothesis, obesity or hypercholesterolemia may counterintuitively be protective and associated with greater survival in certain groups of people, such as elderly individuals, dialysis patients, or those with chronic disease states and wasting syndrome (cachexia), whereas normal to low body mass index or normal values of serum cholesterol may be detrimental and associated with worse mortality. Kalantar-Zadeh is also known for his expertise in kidney dialysis therapy, including incremental dialysis, as well as renal nutrition. He is the brother of Kourosh Kalantar-zadeh, who is an Australian scientist involved in research in the fields of materials sciences, nanotechnology, and transducers.

<i>Journal of Cachexia, Sarcopenia and Muscle</i> Academic journal

The Journal of Cachexia, Sarcopenia and Muscle is a quarterly peer-reviewed medical journal that covers research relevant to changes in body composition, especially cachexia and sarcopenia, as consequences of chronic illnesses or of the aging process, respectively. It was established in 2010 and was originally published by Springer Science+Business Media. As of January 2015, the journal is published by Wiley-Blackwell in association with the Society on Sarcopenia, Cachexia and Wasting Disorders. The founding editors-in-chief are Stefan D. Anker and Stephan von Haehling. As of November 2016, the journal has two daughter journals entitled JCSM - Clinical Reports and JCSM - Rapid Communications, dedicated to clinical and basic science, respectively.

Juven is a medical food that is manufactured by Abbott Laboratories and used to provide nutritional support under the care of a physician in individuals with muscle wasting due to AIDS or cancer, to promote wound healing following surgery or injury, or when otherwise recommended by a medical professional. It is a powdered nutritional supplement that contains 3 grams of calcium β-hydroxy β-methylbutyrate, 14 grams of L-arginine, and 14 grams of L-glutamine per two daily servings.

<span class="mw-page-title-main">Stefan D. Anker</span> German cardiologist

Stefan D. Anker is Head of Field “Tissue Homeostasis and Cachexia" at Charité University, Berlin, Germany. Previously, he was Professor of Innovative Clinical Trials at University Medical Center Göttingen in Germany. The main focus of the Innovative Clinical Trials department was research in the field of chronic heart failure, including the development and clinical testing of new therapies.

A renal diet is a diet aimed at keeping levels of fluids, electrolytes, and minerals balanced in the body in individuals with chronic kidney disease or who are on dialysis. Dietary changes may include the restriction of fluid intake, protein, and electrolytes including sodium, phosphorus, and potassium. Calories may also be supplemented if the individual is losing weight undesirably.

References

  1. ↑ What is cancer cachexia
  2. ↑ Farkas, Jerneja; von Haehling, Stephan; Kalantar-Zadeh, Kamyar; Morley, John E.; Anker, Stefan D.; Lainscak, Mitja (7 December 2016). "Cachexia as a major public health problem: frequent, costly, and deadly". Journal of Cachexia, Sarcopenia and Muscle. 4 (3): 173–178. doi:10.1007/s13539-013-0105-y. ISSN   2190-5991. PMC   3774921 . PMID   23539127.
  3. ↑ McDaniels, Andrea K. "Groups seek better diagnosis and treatment of debilitating muscle loss in seniors". baltimoresun.com. Retrieved 9 February 2018.
  4. ↑ Lok, Corie (10 December 2015). "Cachexia: The last illness". Nature. 528 (7581): 182–183. Bibcode:2015Natur.528..182L. doi: 10.1038/528182a . PMID   26659165. S2CID   4469244.
  5. ↑ Miller, Kelli. "What Is Cardiac Cachexia?". WebMD. Retrieved 2 May 2022.
  6. ↑ "Cachexia". YouTube .
  7. ↑ "Cachexia: Symptoms, Treatment, and Outlook". Medical News Today. Retrieved 24 January 2017.
  8. ↑ von Haehling, Stephan; Anker, Markus S.; Anker, Stefan D. (1 December 2016). "Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016". Journal of Cachexia, Sarcopenia and Muscle. 7 (5): 507–509. doi:10.1002/jcsm.12167. ISSN   2190-6009. PMC   5114624 . PMID   27891294.
  9. ↑ "Curriculum vitae" (PDF).[ permanent dead link ]
  10. ↑ "One of the nation' foremost authorities on geriatrics". Saint Louis University. Archived from the original on 20 December 2016. Retrieved 7 December 2016.
  11. ↑ "The Society On Sarcopenia, Cachexia & Wasting Disorders Announces Its 1st Cancer Cachexia Conference In Boston, USA". Newswire.
  12. ↑ "Society on sarcopenia, cachexia and wasting disorders". research.longfonds.nl. Retrieved 7 December 2016.[ permanent dead link ]
  13. ↑ "Journal of Cachexia, Sarcopenia and Muscle - Society Information -". Journal of Cachexia, Sarcopenia and Muscle. Wiley Online Library. 2018. doi: 10.1007/13539.2190-6009 . hdl: 10807/147340 .
  14. ↑ http://990s.foundationcenter.org/990_pdf_archive/800/800419218/800419218_201212_990.pdf [ bare URL PDF ]
  15. ↑ "ESC Board". www.escardio.org. Retrieved 7 December 2016.
  16. ↑ Coats, Andrew JS (2002). "Origin of symptoms in patients with cachexia with special reference to weakness and shortness of breath". International Journal of Cardiology. 85 (1): 133–139. doi:10.1016/s0167-5273(02)00242-5. PMID   12163218.
  17. ↑ "This Potentially Fatal Syndrome Makes Your Body Literally Waste Away—And It's More Common Than You Know". Prevention. 27 September 2017. Retrieved 9 February 2018.
  18. ↑ "Regulatory Recognition Key to Moving Forward on Sarcopenia: Interview with Dr. Bill Evans, GSK". 13 September 2012.
  19. ↑ "Luigi Ferrucci named NIA scientific director | National Institute on Aging". Archived from the original on 20 December 2016. Retrieved 8 December 2016.
  20. ↑ "editorial". Clinical Nutrition.
  21. ↑ "Obituary - Kenneth Fearon, professor of surgical oncology". HeraldScotland. 16 September 2016. Retrieved 7 December 2016.
  22. ↑ Fearon, Kenneth; Strasser, Florian; Anker, Stefan D.; Bosaeus, Ingvar; Bruera, Eduardo; Fainsinger, Robin L.; Jatoi, Aminah; Loprinzi, Charles; MacDonald, Neil (1 May 2011). "Definition and classification of cancer cachexia: an international consensus". The Lancet. Oncology. 12 (5): 489–495. doi:10.1016/S1470-2045(10)70218-7. ISSN   1474-5488. PMID   21296615.
  23. ↑ Anker, Markus S.; von Haehling, Stephan; Springer, Jochen; Banach, Maciej; Anker, Stefan D. (21 February 2013). "Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology". Archives of Medical Science. 9 (1): 166–171. doi:10.5114/aoms.2013.33356. ISSN   1734-1922. PMC   3598129 . PMID   23515589.
  24. ↑ "Abstracts of the 5th Cachexia Conference, Barcelona, Spain, December 5–8, 2009". Journal of Cachexia, Sarcopenia and Muscle. 1 (1): 43–128. 1 September 2010. doi:10.1007/s13539-010-0001-7. ISSN   2190-6009. PMC   3060650 . PMID   22477519.
  25. ↑ "5th Cachexia conference" (PDF). 5–8 December 2009. Archived from the original on 4 November 2011. Retrieved 1 July 2023.{{cite web}}: CS1 maint: unfit URL (link)
  26. ↑ "Elderly Women Prefer Death to Suffering a Hip Fracture". HuffPost . 11 June 2014.
  27. ↑ "Congress Report - 7th Cachexia Conference Kobe/Osaka, Japan, December 9−11, 2013 | Literature watch | Cancer Cachexia".[ permanent dead link ]
  28. ↑ https://www.goedoc.uni-goettingen.de/goescholar/bitstream/handle/1/13727/jcsm12110.pdf?sequence=1 Archived 21 December 2016 at the Wayback Machine [ bare URL PDF ]
  29. ↑ von Haehling, S; Anker, SD (22 February 2016). "The times they are a-changin': the Cachexia Conference goes annual". Journal of Cachexia, Sarcopenia and Muscle. 7 (1): 3–4. doi:10.1002/jcsm.12110. PMC   4771211 . PMID   27066313.
  30. ↑ "牡丹江市矿山设备经销部". cancercachexia2016.
  31. ↑ "SINU – Società Italiana di Nutrizione Umana" (PDF).
  32. ↑ von Haehling, Stephan; Anker, Stefan D. (1 September 2010). "Cachexia as a major underestimated and unmet medical need: facts and numbers". Journal of Cachexia, Sarcopenia and Muscle. 1 (1): 1–5. doi:10.1007/s13539-010-0002-6. ISSN   2190-6009. PMC   3060651 . PMID   21475699.
  33. ↑ Group, Helsinn. "Helsinn Initiates Extension Study in Late-Stage Anamorelin Clinical Program for Non-Small Cell Lung /PR Newswire UK/". www.prnewswire.co.uk. Retrieved 8 December 2016.
  34. ↑ "Lundbeckfond Ventures ' MID-STAGE CLINICAL STUDY OF WASTING DISEASE THERAPEUTIC MT-102 SHOWS REVERSAL OF CANCER-RELATED WASTING". www.lundbeckfonden.com. Retrieved 12 December 2016.[ permanent dead link ]
  35. ↑ "6th Cachexia Conference: Lisa Niemi-Swayze Slated as Keynote Speaker at SCWD Charity Dinner". www.newswire.com. Retrieved 7 December 2016.
  36. ↑ "Abstracts of the 6th Cachexia Conference, Milan, Italy, December 8–10, 2011 (Part 2)". Journal of Cachexia, Sarcopenia and Muscle. 3 (1): 51–68. 31 January 2012. doi:10.1007/s13539-012-0056-8. ISSN   2190-5991. PMC   3302985 . PMID   22460563.
  37. ↑ Ebner, Nicole; Werner, Claudia G.; Doehner, Wolfram; Anker, Stefan D.; Haehling, Stephan von (2 March 2012). "Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference". Journal of Cachexia, Sarcopenia and Muscle. 3 (1): 45–50. doi:10.1007/s13539-012-0061-y. ISSN   2190-5991. PMC   3302986 . PMID   22460618.
  38. ↑ Morley, John E.; Abbatecola, Angela Marie; Argiles, Josep M.; Baracos, Vickie; Bauer, Juergen; Bhasin, Shalender; Cederholm, Tommy; Coats, Andrew J. Stewart; Cummings, Steven R. (1 July 2011). "Sarcopenia with limited mobility: an international consensus". Journal of the American Medical Directors Association. 12 (6): 403–409. doi:10.1016/j.jamda.2011.04.014. ISSN   1538-9375. PMC   5100674 . PMID   21640657.
  39. ↑ Evans, William J.; Morley, John E.; Argilés, Josep; Bales, Connie; Baracos, Vickie; Guttridge, Denis; Jatoi, Aminah; Kalantar-Zadeh, Kamyar; Lochs, Herbert (1 December 2008). "Cachexia: a new definition". Clinical Nutrition. 27 (6): 793–799. doi:10.1016/j.clnu.2008.06.013. ISSN   1532-1983. PMID   18718696. S2CID   206821612.
  40. ↑ Advances in Food and Nutrition Research. Academic Press. 30 January 2014. ISBN   9780128003688.
  41. ↑ morley, john (2011). "Sarcopenia With Limited Mobility: An International Consensus". Journal of the American Medical Directors Association. 12 (6): 403–409. doi:10.1016/j.jamda.2011.04.014. PMC   5100674 . PMID   21640657.
  42. ↑ Argilés, Josep M.; López-Soriano, Francisco J.; Toledo, Míriam; Betancourt, Angelica; Serpe, Roberto; Busquets, Sílvia (8 December 2016). "The cachexia score (CASCO): a new tool for staging cachectic cancer patients". Journal of Cachexia, Sarcopenia and Muscle. 2 (2): 87–93. doi:10.1007/s13539-011-0027-5. ISSN   2190-5991. PMC   3117995 . PMID   21766054.
  43. ↑ Morley, John E.; Argiles, Josep M.; Evans, William J.; Bhasin, Shalender; Cella, David; Deutz, Nicolaas E. P.; Doehner, Wolfram; Fearon, Ken C. H.; Ferrucci, Luigi (1 July 2010). "Nutritional recommendations for the management of sarcopenia". Journal of the American Medical Directors Association. 11 (6): 391–396. doi:10.1016/j.jamda.2010.04.014. ISSN   1538-9375. PMC   4623318 . PMID   20627179.
  44. ↑ Definition of Sarcopenia
  45. ↑ Watson, Ronald Ross; Preedy, Victor R. (1 January 2013). Bioactive Food as Dietary Interventions for the Aging Population. Academic Press. ISBN   9780123971555.
  46. ↑ Wiley-Blackwell online library
  47. ↑ von Haehling, Stephan; Anker, Stefan D. (18 November 2018). "Once I get on a puzzle, I can't get off: Cachexia and wasting in 2018". Journal of Cachexia, Sarcopenia and Muscle. 9 (6): 1021–1022. doi:10.1002/jcsm.12366. ISSN   2190-5991. PMC   6240749 . PMID   30450844.
  48. ↑ Journal of Cachexia, Sarcopenia and muscle
  49. ↑ von Haehling, Stephan; Anker, Stefan D. (1 September 2015). "Moving on up: the Journal of Cachexia, Sarcopenia and Muscle". Journal of Cachexia, Sarcopenia and Muscle. 6 (3): 193–196. doi:10.1002/jcsm.12064. ISSN   2190-6009. PMC   4575549 . PMID   26401464.
  50. ↑ Mantovani, Giovanni (2006). Cachexia and Wasting: A Modern Approach. Milan: Springer. ISBN   978-8847004719.
  51. ↑ Anker, Stefan D.; Morley, John E (1 December 2015). "Cachexia: a nutritional syndrome?". Journal of Cachexia, Sarcopenia and Muscle. 6 (4): 269–271. doi:10.1002/jcsm.12088. ISSN   2190-6009. PMC   4670732 . PMID   26675043.
  52. ↑ Evans, William J. (1 April 2010). "Skeletal muscle loss: cachexia, sarcopenia, and inactivity". The American Journal of Clinical Nutrition. 91 (4): 1123S–1127S. doi: 10.3945/ajcn.2010.28608A . ISSN   0002-9165. PMID   20164314.
  53. ↑ Morley, John E. (26 September 2016). "Frailty and sarcopenia in elderly". Wiener Klinische Wochenschrift. 128 (Suppl 7): 439–445. doi:10.1007/s00508-016-1087-5. ISSN   1613-7671. PMID   27670855. S2CID   20112072.
  54. ↑ "Patients Suffering From Cachexia Need Nutritional Support". Cure Today. Retrieved 9 February 2018.
  55. ↑ von Haehling, Stephan; Anker, Markus S.; Anker, Stefan D. (1 December 2016). "Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016". Journal of Cachexia, Sarcopenia and Muscle. 7 (5): 507–509. doi:10.1002/jcsm.12167. ISSN   2190-6009. PMC   5114624 . PMID   27891294.
  56. ↑ Green, Brent (6 December 2011). "Follow The Boomer Money: End Of Sarcopenia, Compression Of Morbidity". The Huffington Post. Retrieved 7 December 2016.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.